The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.
本发明提供了一种用于治疗、改善或预防由于谷
氨酸转运体活性异常降低或中枢神经系统细胞外谷
氨酸浓度异常增加而引起、诱导或特征化的疾病或疾病的化合物。在某些实施例中,该化合物刺激谷
氨酸转运体。